CTOs on the Move

Allcells LLC

www.allcells.com

 
Allcells LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.allcells.com
  • 5858 Horton St Ste 360
    Emeryville, CA USA 94608
  • Phone: 510.450.3900

Executives

Name Title Contact Details

Similar Companies

BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Dow Pharmaceutical Sciences

Dow Pharmaceutical Sciences is a Petaluma, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NewNeural

NewNeural is a Naperville, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Berkeley Lights

Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect™ chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain. Berkeley Lights` Beacon® and Lightning™ systems and Culture Station™ instrument are for research use only. Not for use in diagnostic procedures.

Affinivax

Affinivax is a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines designed to induce a broad and robust protective immune response to both disease-relevant polysaccharides and disease-relevant proteins in a single vaccine. Affinivax designs each of its vaccine candidates to optimize the protective immune response to one or both of these antigens utilizing the distinctive plug-and-play nature of its proprietary MAPS™ technology platform, presenting the potential opportunity to make a significant step forward in addressing major healthcare challenges posed by novel and resistant infectious diseases. Affinivax was founded in 2014 with a seed investment from the Bill & Melinda Gates Foundation and an exclusive license to the MAPS technology from Boston Children`s Hospital.